Donepezil - NDSRI's
References
FAQ's
References
- Sugimoto, Hachiro; Tsuchiya, Yutaka; Higurashi, Kunizou; Karibe, Norio; Iimura, Yuoichi; Sasaki, Atsushi; Yamanashi, Yoshiharu; Ogura, Hiroo; Araki, Shin, 1,4-Substituted piperidines as acetylcholinesterase inhibitors and their use for the treatment of Alzheimer's disease, EP296560B1, Dec 28, 1988, Eisai Co., Ltd., Japan
- Pappa, Horacio; Farru, Romina; Vilanova, Paula Otano; Palacios, Marcelo; Pizzorno, Maria Teresa, A new HPLC method to determine Donepezil hydrochloride in tablets, Journal of Pharmaceutical and Biomedical Analysis, Volume: 27, Issue: 1-2, Pages: 177-182, 2002, DOI: (10.1016/s0731-7085(01)00499-x)
Frequently Asked Questions
Can Donepezil impurities affect the therapeutic efficacy of the drug?
Some impurities may impact the pharmacological activity of Donepezil, leading to reduced efficacy or adverse effects in patients.
What is the impact of impurities on the stability of Donepezil?
Impurities can affect the stability of Donepezil, leading to a decrease in its shelf life.
How are impurities detected in Donepezil?
Impurities in Donepezil can be detected using various analytical techniques such as HPLC.
How can the formation of impurities be minimized during the synthetic process?
The formation of impurities can be minimized by optimizing the synthesis process, using high-quality raw materials, and maintaining strict quality control measures.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.